Phase II trial of saracatinib (AZD0530), an oral src-inhibitor for the treatment of patients with hormone receptor negative metastatic breast cancer

BACKGROUND: Src activation is associated with cell migration, proliferation and metastasis. Saracatinib is an oral, tyrosine kinase inhibitor (TKI) selective for Src. We performed this trial to evaluate the efficacy and safety of saracatinib monotherapy in patients with estrogen receptor (ER)- and p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gucalp, Ayca, Sparano, Joseph A., Caravelli, James, Santamauro, Jean, Patil, Sujata, Abbruzzi, Alyson, Pellegrino, Christine, Bromberg, Jackie, Dang, Chau, Theodoulou, Maria, Massague, Joan, Norton, Larry, Hudis, Clifford, Traina, Tiffany A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3222913/
https://ncbi.nlm.nih.gov/pubmed/21729667
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2011.03.021
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados